Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Personalis, Inc.PSNL · Entity 4572 | Director | May 12, 2026 | May 14, 2026 |
| QuidelOrtho CorpQDEL · Entity 4986 | Director | June 25, 2026 | June 29, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Personalis, Inc.
Report date May 12, 2026 · Filed May 14, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 6,250 |
Reported balance
After 2026-05-12 transaction · row 1
1 source rowRow 1 · 2026-05-12 · Grant · Acquired 6,250 · Balance 6,250 F1: Each share is represented by a restricted stock unit ("RSU"). Each RSU represents a contingent right to receive one share of the Issuer's common stock upon settlement. 100% of the shares subject to the RSU shall vest on the earlier of the one-year anniversary of the grant date or the day prior to the Company's next annual meeting of stockholders occurring after the grant date, subject to the reporting person's Continuous Service (as defined in the Company's 2019 Equity Incentive Plan (the "2019 Plan")) through the vesting date. In the event of a Change in Control (as defined in the 2019 Plan), the shares underlying the RSU shall vest immediately prior to the effectiveness of such Change in Control. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.04 · Expires 2036-05-12 | Direct | 37,500 |
Reported balance
After 2026-05-12 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-05-12 · Grant · Acquired 37,500 · Balance 37,500 F2: 100% of the shares subject to the option shall vest on the earlier of the one-year anniversary of the grant date or the day prior to the Company's next annual meeting of stockholders occurring after the grant date, subject to the reporting person's Continuous Service (as defined in the 2019 Plan) through the vesting date. In the event of a Change in Control (as defined in the 2019 Plan), the shares underlying the option shall vest and become exercisable immediately prior to the effectiveness of such Change in Control. |
Filing footnotes · ownership attribution and instrument terms
F1: Each share is represented by a restricted stock unit ("RSU"). Each RSU represents a contingent right to receive one share of the Issuer's common stock upon settlement. 100% of the shares subject to the RSU shall vest on the earlier of the one-year anniversary of the grant date or the day prior to the Company's next annual meeting of stockholders occurring after the grant date, subject to the reporting person's Continuous Service (as defined in the Company's 2019 Equity Incentive Plan (the "2019 Plan")) through the vesting date. In the event of a Change in Control (as defined in the 2019 Plan), the shares underlying the RSU shall vest immediately prior to the effectiveness of such Change in Control.
F2: 100% of the shares subject to the option shall vest on the earlier of the one-year anniversary of the grant date or the day prior to the Company's next annual meeting of stockholders occurring after the grant date, subject to the reporting person's Continuous Service (as defined in the 2019 Plan) through the vesting date. In the event of a Change in Control (as defined in the 2019 Plan), the shares underlying the option shall vest and become exercisable immediately prior to the effectiveness of such Change in Control.
QuidelOrtho Corp
Report date June 25, 2026 · Filed June 29, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Restricted Stock Units (Equity Grant)SEC Table II · derivative / convertible security | Direct | 15,532 |
Reported balance
After 2026-06-25 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-25 · Grant · Acquired 15,532 · Balance 15,532 F1: Each restricted stock unit represents the right to receive one share of QuidelOrtho Corporation common stock. F2: The restricted stock units will vest on June 25, 2027. |
| Restricted Stock Units (Converted)SEC Table II · derivative / convertible security | Direct | 6,656 |
Reported balance
After 2026-06-25 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-06-25 · Grant · Acquired 6,656 · Balance 6,656 F1: Each restricted stock unit represents the right to receive one share of QuidelOrtho Corporation common stock. F3: The restricted stock units were received in lieu of cash payments to the reporting person for certain retainer and Board of Director service-related fees under a deferred compensation program applicable to participating non-employee directors. Release of vested restricted stock units will occur according to the elected deferral schedule. F4: 1,664 shares vested on June 25, 2026, 1,664 shares will vest on September 25, 2026, 1,664 shares will vest on December 25, 2026, and 1,664 shares will vest on March 25, 2027. |
| Restricted Stock Units (Premium)SEC Table II · derivative / convertible security | Direct | 1,997 |
Reported balance
After 2026-06-25 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-06-25 · Grant · Acquired 1,997 · Balance 1,997 F1: Each restricted stock unit represents the right to receive one share of QuidelOrtho Corporation common stock. F2: The restricted stock units will vest on June 25, 2027. F3: The restricted stock units were received in lieu of cash payments to the reporting person for certain retainer and Board of Director service-related fees under a deferred compensation program applicable to participating non-employee directors. Release of vested restricted stock units will occur according to the elected deferral schedule. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit represents the right to receive one share of QuidelOrtho Corporation common stock.
F2: The restricted stock units will vest on June 25, 2027.
F3: The restricted stock units were received in lieu of cash payments to the reporting person for certain retainer and Board of Director service-related fees under a deferred compensation program applicable to participating non-employee directors. Release of vested restricted stock units will occur according to the elected deferral schedule.
F4: 1,664 shares vested on June 25, 2026, 1,664 shares will vest on September 25, 2026, 1,664 shares will vest on December 25, 2026, and 1,664 shares will vest on March 25, 2027.
Past disclosures · reporting ended (2)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Evoke Pharma Inc
Report date December 17, 2025 · Filed December 17, 2025
Section 16 reporting ended · disclosed 2025-12-17. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.41 | Direct | 0 |
Reported balance
After 2025-12-17 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-12-17 · Disposition to issuer · Disposed 1,187 · Balance 0 F1: In connection with that certain Agreement and Plan of Merger, dated as of November 3, 2025 (the "Merger Agreement"), by and among the Issuer, QOL Medical, LLC ("Parent") and QOL-EOS Merger Sub, Inc., a wholly owned subsidiary of Parent ("Merger Sub"), Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the "Effective Time"), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent. F2: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock ("Company Option") outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) $11.00, less (y) the per share exercise price of such Company Option. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.45 | Direct | 0 |
Reported balance
After 2025-12-17 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2025-12-17 · Disposition to issuer · Disposed 5,833 · Balance 0 F1: In connection with that certain Agreement and Plan of Merger, dated as of November 3, 2025 (the "Merger Agreement"), by and among the Issuer, QOL Medical, LLC ("Parent") and QOL-EOS Merger Sub, Inc., a wholly owned subsidiary of Parent ("Merger Sub"), Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the "Effective Time"), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent. F2: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock ("Company Option") outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) $11.00, less (y) the per share exercise price of such Company Option. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.45 | Direct | 0 |
Reported balance
After 2025-12-17 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2025-12-17 · Disposition to issuer · Disposed 1,187 · Balance 0 F1: In connection with that certain Agreement and Plan of Merger, dated as of November 3, 2025 (the "Merger Agreement"), by and among the Issuer, QOL Medical, LLC ("Parent") and QOL-EOS Merger Sub, Inc., a wholly owned subsidiary of Parent ("Merger Sub"), Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the "Effective Time"), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent. F2: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock ("Company Option") outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) $11.00, less (y) the per share exercise price of such Company Option. |
Filing footnotes · ownership attribution and instrument terms
F1: In connection with that certain Agreement and Plan of Merger, dated as of November 3, 2025 (the "Merger Agreement"), by and among the Issuer, QOL Medical, LLC ("Parent") and QOL-EOS Merger Sub, Inc., a wholly owned subsidiary of Parent ("Merger Sub"), Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the "Effective Time"), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent.
F2: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock ("Company Option") outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) $11.00, less (y) the per share exercise price of such Company Option.
QUIDEL CORP /DE/
Report date May 27, 2022 · Filed June 01, 2022
Section 16 reporting ended · disclosed 2022-06-01. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2022-05-27 transaction · row 1
1 source rowRow 1 · 2022-05-27 · Disposition to issuer · Disposed 18,684 · Balance 0 F1: Pursuant to the Business Combination Agreement, dated as of December 22, 2021 (the "Business Combination Agreement") by and among Quidel Corporation ("Quidel"), Ortho Clinical Diagnostics Holdings plc, QuidelOrtho Corporation ("QuidelOrtho"), Orca Holdco, Inc., Laguna Merger Sub, Inc. and Orca Holdco 2, Inc., each share of common stock of Quidel beneficially owned by the Reporting Person at the effective time of the transaction contemplated by the Business Combination Agreement will be exchanged for one share of common stock of QuidelOrtho. |
| Non-Qualified Stock OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $27.91 · Expires 2024-11-17 | Direct | 0 |
Reported balance
After 2022-05-27 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2022-05-27 · Disposition to issuer · Disposed 3,333 · Balance 0 F2: Pursuant to the Business Combination Agreement, the Quidel Non-Qualified Stock Options will be converted into an equal number of Non-Qualified Stock Options to purchase shares of common stock of QuidelOrtho on the same terms and conditions (including applicable vesting conditions). F3: Vested in full. |
| Non-Qualified Stock OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $22.86 · Expires 2025-05-05 | Direct | 0 |
Reported balance
After 2022-05-27 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2022-05-27 · Disposition to issuer · Disposed 7,021 · Balance 0 F2: Pursuant to the Business Combination Agreement, the Quidel Non-Qualified Stock Options will be converted into an equal number of Non-Qualified Stock Options to purchase shares of common stock of QuidelOrtho on the same terms and conditions (including applicable vesting conditions). F3: Vested in full. |
| Non-Qualified Stock OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $15.74 · Expires 2026-05-17 | Direct | 0 |
Reported balance
After 2022-05-27 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2022-05-27 · Disposition to issuer · Disposed 7,021 · Balance 0 F2: Pursuant to the Business Combination Agreement, the Quidel Non-Qualified Stock Options will be converted into an equal number of Non-Qualified Stock Options to purchase shares of common stock of QuidelOrtho on the same terms and conditions (including applicable vesting conditions). F3: Vested in full. |
| Non-Qualified Stock OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $24.80 · Expires 2027-05-16 | Direct | 0 |
Reported balance
After 2022-05-27 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2022-05-27 · Disposition to issuer · Disposed 5,065 · Balance 0 F2: Pursuant to the Business Combination Agreement, the Quidel Non-Qualified Stock Options will be converted into an equal number of Non-Qualified Stock Options to purchase shares of common stock of QuidelOrtho on the same terms and conditions (including applicable vesting conditions). F3: Vested in full. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2022-05-27 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2022-05-27 · Disposition to issuer · Disposed 1,050 · Balance 0 F4: Each restricted stock unit represents the right to receive one share of Quidel common stock. F5: Pursuant to the Business Combination Agreement, the Quidel restricted stock units will be converted into an equal number of restricted stock units representing the right to receive shares of common stock of QuidelOrtho on the same terms and conditions (including applicable vesting conditions). F6: Release of restricted stock units was deferred pursuant to Quidel's deferred compensation program applicable to participating non-employee directors and will occur according to the elected deferral schedule. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2022-05-27 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2022-05-27 · Disposition to issuer · Disposed 315 · Balance 0 F4: Each restricted stock unit represents the right to receive one share of Quidel common stock. F5: Pursuant to the Business Combination Agreement, the Quidel restricted stock units will be converted into an equal number of restricted stock units representing the right to receive shares of common stock of QuidelOrtho on the same terms and conditions (including applicable vesting conditions). F6: Release of restricted stock units was deferred pursuant to Quidel's deferred compensation program applicable to participating non-employee directors and will occur according to the elected deferral schedule. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2022-05-27 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2022-05-27 · Disposition to issuer · Disposed 328 · Balance 0 F4: Each restricted stock unit represents the right to receive one share of Quidel common stock. F5: Pursuant to the Business Combination Agreement, the Quidel restricted stock units will be converted into an equal number of restricted stock units representing the right to receive shares of common stock of QuidelOrtho on the same terms and conditions (including applicable vesting conditions). F6: Release of restricted stock units was deferred pursuant to Quidel's deferred compensation program applicable to participating non-employee directors and will occur according to the elected deferral schedule. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2022-05-27 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2022-05-27 · Disposition to issuer · Disposed 98 · Balance 0 F4: Each restricted stock unit represents the right to receive one share of Quidel common stock. F5: Pursuant to the Business Combination Agreement, the Quidel restricted stock units will be converted into an equal number of restricted stock units representing the right to receive shares of common stock of QuidelOrtho on the same terms and conditions (including applicable vesting conditions). F6: Release of restricted stock units was deferred pursuant to Quidel's deferred compensation program applicable to participating non-employee directors and will occur according to the elected deferral schedule. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2022-05-27 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2022-05-27 · Disposition to issuer · Disposed 512 · Balance 0 F4: Each restricted stock unit represents the right to receive one share of Quidel common stock. F5: Pursuant to the Business Combination Agreement, the Quidel restricted stock units will be converted into an equal number of restricted stock units representing the right to receive shares of common stock of QuidelOrtho on the same terms and conditions (including applicable vesting conditions). F6: Release of restricted stock units was deferred pursuant to Quidel's deferred compensation program applicable to participating non-employee directors and will occur according to the elected deferral schedule. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2022-05-27 transaction · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · 2022-05-27 · Disposition to issuer · Disposed 153 · Balance 0 F4: Each restricted stock unit represents the right to receive one share of Quidel common stock. F5: Pursuant to the Business Combination Agreement, the Quidel restricted stock units will be converted into an equal number of restricted stock units representing the right to receive shares of common stock of QuidelOrtho on the same terms and conditions (including applicable vesting conditions). F6: Release of restricted stock units was deferred pursuant to Quidel's deferred compensation program applicable to participating non-employee directors and will occur according to the elected deferral schedule. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the Business Combination Agreement, dated as of December 22, 2021 (the "Business Combination Agreement") by and among Quidel Corporation ("Quidel"), Ortho Clinical Diagnostics Holdings plc, QuidelOrtho Corporation ("QuidelOrtho"), Orca Holdco, Inc., Laguna Merger Sub, Inc. and Orca Holdco 2, Inc., each share of common stock of Quidel beneficially owned by the Reporting Person at the effective time of the transaction contemplated by the Business Combination Agreement will be exchanged for one share of common stock of QuidelOrtho.
F2: Pursuant to the Business Combination Agreement, the Quidel Non-Qualified Stock Options will be converted into an equal number of Non-Qualified Stock Options to purchase shares of common stock of QuidelOrtho on the same terms and conditions (including applicable vesting conditions).
F3: Vested in full.
F4: Each restricted stock unit represents the right to receive one share of Quidel common stock.
F5: Pursuant to the Business Combination Agreement, the Quidel restricted stock units will be converted into an equal number of restricted stock units representing the right to receive shares of common stock of QuidelOrtho on the same terms and conditions (including applicable vesting conditions).
F6: Release of restricted stock units was deferred pursuant to Quidel's deferred compensation program applicable to participating non-employee directors and will occur according to the elected deferral schedule.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 25, 2026 Filed Jun 29, 2026 22:01 UTC | QuidelOrtho Corp QDEL · Entity 4986 | GrantRestricted Stock Units (Premium) · Derivative | 1,997 | $0.00 | $0.00 |
DisclosureSEC source: 0001065168-26-000006 · wk-form4_1782770501.xml · derivative · entry 3 WIDDER KENNETH J · CIK 0001065168 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,997 Underlying: Common Stock · 1,997 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of QuidelOrtho Corporation common stock. F2 · derivative.exercise_date: The restricted stock units will vest on June 25, 2027. F3 · derivative.exercise_date: The restricted stock units were received in lieu of cash payments to the reporting person for certain retainer and Board of Director service-related fees under a deferred compensation program applicable to participating non-employee directors. Release of vested restricted stock units will occur according to the elected deferral schedule. F2 · derivative.expiration_date: The restricted stock units will vest on June 25, 2027. F3 · derivative.expiration_date: The restricted stock units were received in lieu of cash payments to the reporting person for certain retainer and Board of Director service-related fees under a deferred compensation program applicable to participating non-employee directors. Release of vested restricted stock units will occur according to the elected deferral schedule. Read SEC document |
| June 25, 2026 Filed Jun 29, 2026 22:01 UTC | QuidelOrtho Corp QDEL · Entity 4986 | GrantRestricted Stock Units (Converted) · Derivative | 6,656 | $0.00 | $0.00 |
DisclosureSEC source: 0001065168-26-000006 · wk-form4_1782770501.xml · derivative · entry 2 WIDDER KENNETH J · CIK 0001065168 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,656 Underlying: Common Stock · 6,656 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of QuidelOrtho Corporation common stock. F3 · derivative.exercise_date: The restricted stock units were received in lieu of cash payments to the reporting person for certain retainer and Board of Director service-related fees under a deferred compensation program applicable to participating non-employee directors. Release of vested restricted stock units will occur according to the elected deferral schedule. F4 · derivative.exercise_date: 1,664 shares vested on June 25, 2026, 1,664 shares will vest on September 25, 2026, 1,664 shares will vest on December 25, 2026, and 1,664 shares will vest on March 25, 2027. F3 · derivative.expiration_date: The restricted stock units were received in lieu of cash payments to the reporting person for certain retainer and Board of Director service-related fees under a deferred compensation program applicable to participating non-employee directors. Release of vested restricted stock units will occur according to the elected deferral schedule. F4 · derivative.expiration_date: 1,664 shares vested on June 25, 2026, 1,664 shares will vest on September 25, 2026, 1,664 shares will vest on December 25, 2026, and 1,664 shares will vest on March 25, 2027. Read SEC document |
| June 25, 2026 Filed Jun 29, 2026 22:01 UTC | QuidelOrtho Corp QDEL · Entity 4986 | GrantRestricted Stock Units (Equity Grant) · Derivative | 15,532 | $0.00 | $0.00 |
DisclosureSEC source: 0001065168-26-000006 · wk-form4_1782770501.xml · derivative · entry 1 WIDDER KENNETH J · CIK 0001065168 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,532 Underlying: Common Stock · 15,532 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of QuidelOrtho Corporation common stock. F2 · derivative.exercise_date: The restricted stock units will vest on June 25, 2027. F2 · derivative.expiration_date: The restricted stock units will vest on June 25, 2027. Read SEC document |
| June 06, 2026 Filed Jun 9, 2026 20:07 UTC | QuidelOrtho Corp QDEL · Entity 4986 | Exercise / conversionRestricted Stock Units (Premium) · Derivative | 273 | $0.00 | $0.00 |
DisclosureSEC source: 0001065168-26-000005 · wk-form4_1781035629.xml · derivative · entry 4 WIDDER KENNETH J · CIK 0001065168 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 273 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of QuidelOrtho Corporation common stock. F3 · derivative.exercise_date: Release of restricted stock units was deferred pursuant to QuidelOrtho's deferred compensation program applicable to participating non-employee directors and occurred according to the elected deferred schedule. F3 · derivative.expiration_date: Release of restricted stock units was deferred pursuant to QuidelOrtho's deferred compensation program applicable to participating non-employee directors and occurred according to the elected deferred schedule. Read SEC document |
| June 06, 2026 Filed Jun 9, 2026 20:07 UTC | QuidelOrtho Corp QDEL · Entity 4986 | Exercise / conversionRestricted Stock Units (Converted) · Derivative | 910 | $0.00 | $0.00 |
DisclosureSEC source: 0001065168-26-000005 · wk-form4_1781035629.xml · derivative · entry 3 WIDDER KENNETH J · CIK 0001065168 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 910 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of QuidelOrtho Corporation common stock. F3 · derivative.exercise_date: Release of restricted stock units was deferred pursuant to QuidelOrtho's deferred compensation program applicable to participating non-employee directors and occurred according to the elected deferred schedule. F3 · derivative.expiration_date: Release of restricted stock units was deferred pursuant to QuidelOrtho's deferred compensation program applicable to participating non-employee directors and occurred according to the elected deferred schedule. Read SEC document |
| June 06, 2026 Filed Jun 9, 2026 20:07 UTC | QuidelOrtho Corp QDEL · Entity 4986 | GrantCommon Stock | 273 | $0.00 | $0.00 |
DisclosureSEC source: 0001065168-26-000005 · wk-form4_1781035629.xml · nonDerivative · entry 2 WIDDER KENNETH J · CIK 0001065168 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 45,073 F1 · shares: Reflects release of restricted stock units that were previously reported on a Form 4. Read SEC document |
| June 06, 2026 Filed Jun 9, 2026 20:07 UTC | QuidelOrtho Corp QDEL · Entity 4986 | GrantCommon Stock | 910 | $0.00 | $0.00 |
DisclosureSEC source: 0001065168-26-000005 · wk-form4_1781035629.xml · nonDerivative · entry 1 WIDDER KENNETH J · CIK 0001065168 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 44,800 F1 · shares: Reflects release of restricted stock units that were previously reported on a Form 4. Read SEC document |
| May 29, 2026 Filed Jun 2, 2026 20:10 UTC | QuidelOrtho Corp QDEL · Entity 4986 | Exercise / conversionRestricted Stock Units (Equity Grant) · Derivative | 6,829 | $0.00 | $0.00 |
DisclosureSEC source: 0001065168-26-000003 · wk-form4_1780431045.xml · derivative · entry 2 WIDDER KENNETH J · CIK 0001065168 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,829 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of QuidelOrtho Corporation common stock. F3 · derivative.exercise_date: The restricted stock units vested on May 29, 2026. F3 · derivative.expiration_date: The restricted stock units vested on May 29, 2026. Read SEC document |
| May 29, 2026 Filed Jun 2, 2026 20:10 UTC | QuidelOrtho Corp QDEL · Entity 4986 | GrantCommon Stock | 6,829 | $0.00 | $0.00 |
DisclosureSEC source: 0001065168-26-000003 · wk-form4_1780431045.xml · nonDerivative · entry 1 WIDDER KENNETH J · CIK 0001065168 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 43,890 F1 · shares: Reflects release of restricted stock units that were previously reported on a Form 4. Read SEC document |
| May 12, 2026 Filed May 14, 2026 21:07 UTC | Personalis, Inc. PSNL · Entity 4572 | GrantStock Option (right to buy) · Derivative | 37,500 | $0.00 Strike: $6.04 | $0.00 |
DisclosureSEC source: 0001065168-26-000001 · form4-05142026_090519.xml · derivative · entry 2 WIDDER KENNETH J · CIK 0001065168 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 37,500 Underlying: Common Stock · 37,500 shares Expires 2036-05-12 F2 · derivative.exercise_date: 100% of the shares subject to the option shall vest on the earlier of the one-year anniversary of the grant date or the day prior to the Company's next annual meeting of stockholders occurring after the grant date, subject to the reporting person's Continuous Service (as defined in the 2019 Plan) through the vesting date. In the event of a Change in Control (as defined in the 2019 Plan), the shares underlying the option shall vest and become exercisable immediately prior to the effectiveness of such Change in Control. Read SEC document |
| May 12, 2026 Filed May 14, 2026 21:07 UTC | Personalis, Inc. PSNL · Entity 4572 | GrantCommon Stock | 6,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001065168-26-000001 · form4-05142026_090519.xml · nonDerivative · entry 1 WIDDER KENNETH J · CIK 0001065168 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,250 F1 · shares: Each share is represented by a restricted stock unit ("RSU"). Each RSU represents a contingent right to receive one share of the Issuer's common stock upon settlement. 100% of the shares subject to the RSU shall vest on the earlier of the one-year anniversary of the grant date or the day prior to the Company's next annual meeting of stockholders occurring after the grant date, subject to the reporting person's Continuous Service (as defined in the Company's 2019 Equity Incentive Plan (the "2019 Plan")) through the vesting date. In the event of a Change in Control (as defined in the 2019 Plan), the shares underlying the RSU shall vest immediately prior to the effectiveness of such Change in Control. Read SEC document |
| December 17, 2025 Filed Dec 17, 2025 21:00 UTC | Evoke Pharma Inc EVOK · Entity 71094 | Disposition to issuerStock Option (Right to Buy) · Derivative | 1,187 | Not disclosed Strike: $3.45 | Not disclosed |
DisclosureSEC source: 0001193125-25-322641 · ownership.xml · derivative · entry 3 WIDDER KENNETH J · CIK 0001065168 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,187 shares Expires not disclosed F1 · price: In connection with that certain Agreement and Plan of Merger, dated as of November 3, 2025 (the "Merger Agreement"), by and among the Issuer, QOL Medical, LLC ("Parent") and QOL-EOS Merger Sub, Inc., a wholly owned subsidiary of Parent ("Merger Sub"), Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the "Effective Time"), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent. F2 · price: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock ("Company Option") outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) $11.00, less (y) the per share exercise price of such Company Option. F1 · derivative.exercise_date: In connection with that certain Agreement and Plan of Merger, dated as of November 3, 2025 (the "Merger Agreement"), by and among the Issuer, QOL Medical, LLC ("Parent") and QOL-EOS Merger Sub, Inc., a wholly owned subsidiary of Parent ("Merger Sub"), Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the "Effective Time"), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent. F2 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock ("Company Option") outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) $11.00, less (y) the per share exercise price of such Company Option. F1 · derivative.expiration_date: In connection with that certain Agreement and Plan of Merger, dated as of November 3, 2025 (the "Merger Agreement"), by and among the Issuer, QOL Medical, LLC ("Parent") and QOL-EOS Merger Sub, Inc., a wholly owned subsidiary of Parent ("Merger Sub"), Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the "Effective Time"), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent. F2 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock ("Company Option") outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) $11.00, less (y) the per share exercise price of such Company Option. Read SEC document |
| December 17, 2025 Filed Dec 17, 2025 21:00 UTC | Evoke Pharma Inc EVOK · Entity 71094 | Disposition to issuerStock Option (Right to Buy) · Derivative | 5,833 | Not disclosed Strike: $4.45 | Not disclosed |
DisclosureSEC source: 0001193125-25-322641 · ownership.xml · derivative · entry 2 WIDDER KENNETH J · CIK 0001065168 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,833 shares Expires not disclosed F1 · price: In connection with that certain Agreement and Plan of Merger, dated as of November 3, 2025 (the "Merger Agreement"), by and among the Issuer, QOL Medical, LLC ("Parent") and QOL-EOS Merger Sub, Inc., a wholly owned subsidiary of Parent ("Merger Sub"), Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the "Effective Time"), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent. F2 · price: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock ("Company Option") outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) $11.00, less (y) the per share exercise price of such Company Option. F1 · derivative.exercise_date: In connection with that certain Agreement and Plan of Merger, dated as of November 3, 2025 (the "Merger Agreement"), by and among the Issuer, QOL Medical, LLC ("Parent") and QOL-EOS Merger Sub, Inc., a wholly owned subsidiary of Parent ("Merger Sub"), Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the "Effective Time"), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent. F2 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock ("Company Option") outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) $11.00, less (y) the per share exercise price of such Company Option. F1 · derivative.expiration_date: In connection with that certain Agreement and Plan of Merger, dated as of November 3, 2025 (the "Merger Agreement"), by and among the Issuer, QOL Medical, LLC ("Parent") and QOL-EOS Merger Sub, Inc., a wholly owned subsidiary of Parent ("Merger Sub"), Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the "Effective Time"), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent. F2 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock ("Company Option") outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) $11.00, less (y) the per share exercise price of such Company Option. Read SEC document |
| December 17, 2025 Filed Dec 17, 2025 21:00 UTC | Evoke Pharma Inc EVOK · Entity 71094 | Disposition to issuerStock Option (Right to Buy) · Derivative | 1,187 | Not disclosed Strike: $5.41 | Not disclosed |
DisclosureSEC source: 0001193125-25-322641 · ownership.xml · derivative · entry 1 WIDDER KENNETH J · CIK 0001065168 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,187 shares Expires not disclosed F1 · price: In connection with that certain Agreement and Plan of Merger, dated as of November 3, 2025 (the "Merger Agreement"), by and among the Issuer, QOL Medical, LLC ("Parent") and QOL-EOS Merger Sub, Inc., a wholly owned subsidiary of Parent ("Merger Sub"), Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the "Effective Time"), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent. F2 · price: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock ("Company Option") outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) $11.00, less (y) the per share exercise price of such Company Option. F1 · derivative.exercise_date: In connection with that certain Agreement and Plan of Merger, dated as of November 3, 2025 (the "Merger Agreement"), by and among the Issuer, QOL Medical, LLC ("Parent") and QOL-EOS Merger Sub, Inc., a wholly owned subsidiary of Parent ("Merger Sub"), Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the "Effective Time"), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent. F2 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock ("Company Option") outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) $11.00, less (y) the per share exercise price of such Company Option. F1 · derivative.expiration_date: In connection with that certain Agreement and Plan of Merger, dated as of November 3, 2025 (the "Merger Agreement"), by and among the Issuer, QOL Medical, LLC ("Parent") and QOL-EOS Merger Sub, Inc., a wholly owned subsidiary of Parent ("Merger Sub"), Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the "Effective Time"), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent. F2 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock ("Company Option") outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) $11.00, less (y) the per share exercise price of such Company Option. Read SEC document |
| November 25, 2025 Filed Nov 25, 2025 21:16 UTC | QuidelOrtho Corp QDEL · Entity 4986 | Exercise / conversionNon-Qualified Stock Options · Derivative | 7,021 | $0.00 Strike: $15.74 | $0.00 |
DisclosureSEC source: 0001065168-25-000005 · wk-form4_1764105367.xml · derivative · entry 3 WIDDER KENNETH J · CIK 0001065168 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,021 shares Expires 2026-05-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Vested in full. Read SEC document |
| November 25, 2025 Filed Nov 25, 2025 21:16 UTC | QuidelOrtho Corp QDEL · Entity 4986 | SaleCommon Stock | 4,026 | $27.81 | $111,965.48 |
DisclosureSEC source: 0001065168-25-000005 · wk-form4_1764105367.xml · nonDerivative · entry 2 WIDDER KENNETH J · CIK 0001065168 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 37,061 F1 · price: The weighted average sale price for these transactions was $27.8106 per share, with a range of $27.81 to $27.83. Upon request, the Reporting Person hereby undertakes to provide to staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder, the full information regarding the number of shares sold at each separate price. Read SEC document |
| November 25, 2025 Filed Nov 25, 2025 21:16 UTC | QuidelOrtho Corp QDEL · Entity 4986 | Exercise / conversionCommon Stock | 7,021 | $15.74 | $110,510.54 |
DisclosureSEC source: 0001065168-25-000005 · wk-form4_1764105367.xml · nonDerivative · entry 1 WIDDER KENNETH J · CIK 0001065168 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 41,087 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 29, 2025 Filed Jun 2, 2025 20:20 UTC | QuidelOrtho Corp QDEL · Entity 4986 | GrantRestricted Stock Units (Premium) · Derivative | 878 | $0.00 | $0.00 |
DisclosureSEC source: 0001906324-25-000124 · wk-form4_1748895637.xml · derivative · entry 3 WIDDER KENNETH J · CIK 0001065168 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 878 Underlying: Common Stock · 878 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of QuidelOrtho Corporation common stock. F2 · derivative.exercise_date: The restricted stock units will vest on May 29, 2026. F3 · derivative.exercise_date: The restricted stock units were received in lieu of cash payments to the reporting person for certain retainer and Board of Director service-related fees under a deferred compensation program applicable to participating non-employee directors. Release of vested restricted stock units will occur according to the elected deferral schedule. F2 · derivative.expiration_date: The restricted stock units will vest on May 29, 2026. F3 · derivative.expiration_date: The restricted stock units were received in lieu of cash payments to the reporting person for certain retainer and Board of Director service-related fees under a deferred compensation program applicable to participating non-employee directors. Release of vested restricted stock units will occur according to the elected deferral schedule. Read SEC document |
| May 29, 2025 Filed Jun 2, 2025 20:20 UTC | QuidelOrtho Corp QDEL · Entity 4986 | GrantRestricted Stock Units (Converted) · Derivative | 2,926 | $0.00 | $0.00 |
DisclosureSEC source: 0001906324-25-000124 · wk-form4_1748895637.xml · derivative · entry 2 WIDDER KENNETH J · CIK 0001065168 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,926 Underlying: Common Stock · 2,926 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of QuidelOrtho Corporation common stock. F3 · derivative.exercise_date: The restricted stock units were received in lieu of cash payments to the reporting person for certain retainer and Board of Director service-related fees under a deferred compensation program applicable to participating non-employee directors. Release of vested restricted stock units will occur according to the elected deferral schedule. F4 · derivative.exercise_date: 731 shares vested on May 29, 2025, 731 shares will vest on August 29, 2025, 732 shares will vest on November 29, 2025 and 732 shares will vest on February 28, 2026. F3 · derivative.expiration_date: The restricted stock units were received in lieu of cash payments to the reporting person for certain retainer and Board of Director service-related fees under a deferred compensation program applicable to participating non-employee directors. Release of vested restricted stock units will occur according to the elected deferral schedule. F4 · derivative.expiration_date: 731 shares vested on May 29, 2025, 731 shares will vest on August 29, 2025, 732 shares will vest on November 29, 2025 and 732 shares will vest on February 28, 2026. Read SEC document |
| May 29, 2025 Filed Jun 2, 2025 20:20 UTC | QuidelOrtho Corp QDEL · Entity 4986 | GrantRestricted Stock Units (Equity Grant) · Derivative | 6,829 | $0.00 | $0.00 |
DisclosureSEC source: 0001906324-25-000124 · wk-form4_1748895637.xml · derivative · entry 1 WIDDER KENNETH J · CIK 0001065168 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,829 Underlying: Common Stock · 6,829 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of QuidelOrtho Corporation common stock. F2 · derivative.exercise_date: The restricted stock units will vest on May 29, 2026. F2 · derivative.expiration_date: The restricted stock units will vest on May 29, 2026. Read SEC document |
| May 22, 2025 Filed May 27, 2025 20:30 UTC | QuidelOrtho Corp QDEL · Entity 4986 | Exercise / conversionRestricted Stock Units (Equity Grant) · Derivative | 4,929 | $0.00 | $0.00 |
DisclosureSEC source: 0001906324-25-000100 · wk-form4_1748377816.xml · derivative · entry 2 WIDDER KENNETH J · CIK 0001065168 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,929 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of QuidelOrtho Corporation common stock. F3 · derivative.exercise_date: The restricted stock units vested on May 22, 2025. F3 · derivative.expiration_date: The restricted stock units vested on May 22, 2025. Read SEC document |
| May 22, 2025 Filed May 27, 2025 20:30 UTC | QuidelOrtho Corp QDEL · Entity 4986 | GrantCommon Stock | 4,929 | $0.00 | $0.00 |
DisclosureSEC source: 0001906324-25-000100 · wk-form4_1748377816.xml · nonDerivative · entry 1 WIDDER KENNETH J · CIK 0001065168 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 34,066 F1 · shares: Reflects release of restricted stock units that were previously reported on a Form 4. Read SEC document |
| May 21, 2025 Filed May 22, 2025 21:00 UTC | Evoke Pharma Inc EVOK · Entity 71094 | GrantStock Option (Right to Buy) · Derivative | 1,187 | $0.00 Strike: $3.45 | $0.00 |
DisclosureSEC source: 0000950170-25-076437 · ownership.xml · derivative · entry 1 WIDDER KENNETH J · CIK 0001065168 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,207 Underlying: Common Stock · 1,187 shares Expires 2035-05-20 F1 · derivative.exercise_date: The total number of shares of common stock subject to the option vests on the one-year anniversary of the date of grant, subject to the Reporting Person's continued service to the Issuer through such vesting date. Read SEC document |
| May 18, 2025 Filed May 20, 2025 21:22 UTC | QuidelOrtho Corp QDEL · Entity 4986 | Exercise / conversionRestricted Stock Units (Premium ) · Derivative | 153 | $0.00 | $0.00 |
DisclosureSEC source: 0001906324-25-000074 · wk-form4_1747776149.xml · derivative · entry 4 WIDDER KENNETH J · CIK 0001065168 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 153 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of QuidelOrtho Corporation common stock. F3 · derivative.exercise_date: Release of restricted stock units was deferred pursuant to QuidelOrtho's deferred compensation program applicable to participating non-employee directors and occurred according to the elected deferred schedule. F3 · derivative.expiration_date: Release of restricted stock units was deferred pursuant to QuidelOrtho's deferred compensation program applicable to participating non-employee directors and occurred according to the elected deferred schedule. Read SEC document |
| May 18, 2025 Filed May 20, 2025 21:22 UTC | QuidelOrtho Corp QDEL · Entity 4986 | Exercise / conversionRestricted Stock Units (Converted) · Derivative | 512 | $0.00 | $0.00 |
DisclosureSEC source: 0001906324-25-000074 · wk-form4_1747776149.xml · derivative · entry 3 WIDDER KENNETH J · CIK 0001065168 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 512 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of QuidelOrtho Corporation common stock. F3 · derivative.exercise_date: Release of restricted stock units was deferred pursuant to QuidelOrtho's deferred compensation program applicable to participating non-employee directors and occurred according to the elected deferred schedule. F3 · derivative.expiration_date: Release of restricted stock units was deferred pursuant to QuidelOrtho's deferred compensation program applicable to participating non-employee directors and occurred according to the elected deferred schedule. Read SEC document |
| May 18, 2025 Filed May 20, 2025 21:22 UTC | QuidelOrtho Corp QDEL · Entity 4986 | GrantCommon Stock | 153 | $0.00 | $0.00 |
DisclosureSEC source: 0001906324-25-000074 · wk-form4_1747776149.xml · nonDerivative · entry 2 WIDDER KENNETH J · CIK 0001065168 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 29,137 F1 · shares: Reflects release of restricted stock units that were previously reported on a Form 4. Read SEC document |
| May 18, 2025 Filed May 20, 2025 21:22 UTC | QuidelOrtho Corp QDEL · Entity 4986 | GrantCommon Stock | 512 | $0.00 | $0.00 |
DisclosureSEC source: 0001906324-25-000074 · wk-form4_1747776149.xml · nonDerivative · entry 1 WIDDER KENNETH J · CIK 0001065168 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,984 F1 · shares: Reflects release of restricted stock units that were previously reported on a Form 4. Read SEC document |
| May 16, 2025 Filed May 20, 2025 20:15 UTC | Personalis, Inc. PSNL · Entity 4572 | GrantStock Option (right to buy) · Derivative | 50,000 | $0.00 Strike: $4.95 | $0.00 |
DisclosureSEC source: 0001415889-25-013799 · form4-05202025_080544.xml · derivative · entry 1 WIDDER KENNETH J · CIK 0001065168 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2035-05-16 F1 · derivative.exercise_date: 100% of the shares subject to the option shall vest on the earlier of the one-year anniversary of the grant date or the day prior to the Company's next annual meeting of stockholders occurring after the grant date, subject to the reporting person's Continuous Service (as defined in the Company's 2019 Equity Incentive Plan) through the vesting date. In the event of a Change in Control (as defined in the Company's 2019 Equity Incentive Plan), the shares underlying the option shall vest and become exercisable immediately prior to the effectiveness of such Change in Control. Read SEC document |
| January 28, 2025 Filed Jan 29, 2025 21:30 UTC | Evoke Pharma Inc EVOK · Entity 71094 | GrantStock Option (Right to Buy) · Derivative | 5,833 | $0.00 Strike: $4.45 | $0.00 |
DisclosureSEC source: 0000950170-25-010540 · ownership.xml · derivative · entry 1 WIDDER KENNETH J · CIK 0001065168 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,833 Underlying: Common Stock · 5,833 shares Expires 2035-01-27 F1 · derivative.exercise_date: The total number of shares of common stock subject to the option shall vest one-third of the total number of shares each one-year period after the vesting commencement date, so that the option shall be fully vested on the third anniversary of the vesting commencement date, subject to the Holder's continued service to the Company through each such vesting date. Read SEC document |
| July 19, 2024 Filed Jul 23, 2024 22:43 UTC | QuidelOrtho Corp QDEL · Entity 4986 | Exercise / conversionNon-Qualified Stock Option · Derivative | 3,333 | $0.00 Strike: $27.91 | $0.00 |
DisclosureSEC source: 0000950170-24-085807 · ownership.xml · derivative · entry 2 WIDDER KENNETH J · CIK 0001065168 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,333 shares Expires 2024-11-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: This option award vested in full on May 6, 2015. Read SEC document |
| July 19, 2024 Filed Jul 23, 2024 22:43 UTC | QuidelOrtho Corp QDEL · Entity 4986 | Exercise / conversionCommon Stock | 3,333 | $27.91 | $93,024.03 |
DisclosureSEC source: 0000950170-24-085807 · ownership.xml · nonDerivative · entry 1 WIDDER KENNETH J · CIK 0001065168 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,472 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 24, 2024 Filed May 29, 2024 20:42 UTC | QuidelOrtho Corp QDEL · Entity 4986 | Exercise / conversionRestricted Stock Units (Equity Grant) · Derivative | 2,416 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-066011 · ownership.xml · derivative · entry 2 WIDDER KENNETH J · CIK 0001065168 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,416 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of QuidelOrtho Corporation common stock. F3 · derivative.exercise_date: The restricted stock units vested on May 24, 2024. F3 · derivative.expiration_date: The restricted stock units vested on May 24, 2024. Read SEC document |
| May 24, 2024 Filed May 29, 2024 20:42 UTC | QuidelOrtho Corp QDEL · Entity 4986 | GrantCommon Stock | 2,416 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-066011 · ownership.xml · nonDerivative · entry 1 WIDDER KENNETH J · CIK 0001065168 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,139 F1 · shares: Reflects release of restricted stock units that were previously reported on a Form 4. Read SEC document |
| May 22, 2024 Filed May 23, 2024 22:31 UTC | QuidelOrtho Corp QDEL · Entity 4986 | GrantRestricted Stock Units (Premium) · Derivative | 633 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-064151 · ownership.xml · derivative · entry 3 WIDDER KENNETH J · CIK 0001065168 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 633 Underlying: Common Stock · 633 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of QuidelOrtho Corporation common stock. F2 · derivative.exercise_date: The restricted stock units vest on May 22, 2025. F3 · derivative.exercise_date: The restricted stock units were received in lieu of cash payments to the reporting person for certain retainer and Board of Director service-related fees under a deferred compensation program applicable to participating non-employee directors. Release of vested restricted stock units will occur according to the elected deferral schedule. F2 · derivative.expiration_date: The restricted stock units vest on May 22, 2025. F3 · derivative.expiration_date: The restricted stock units were received in lieu of cash payments to the reporting person for certain retainer and Board of Director service-related fees under a deferred compensation program applicable to participating non-employee directors. Release of vested restricted stock units will occur according to the elected deferral schedule. Read SEC document |
| May 22, 2024 Filed May 23, 2024 22:31 UTC | QuidelOrtho Corp QDEL · Entity 4986 | GrantRestricted Stock Units (Converted) · Derivative | 2,112 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-064151 · ownership.xml · derivative · entry 2 WIDDER KENNETH J · CIK 0001065168 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,112 Underlying: Common Stock · 2,112 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of QuidelOrtho Corporation common stock. F3 · derivative.exercise_date: The restricted stock units were received in lieu of cash payments to the reporting person for certain retainer and Board of Director service-related fees under a deferred compensation program applicable to participating non-employee directors. Release of vested restricted stock units will occur according to the elected deferral schedule. F4 · derivative.exercise_date: 528 shares vested on May 22, 2024, 528 shares will vest on August 22, 2024, 528 shares will vest on November 22, 2024 and 528 shares will vest on February 22, 2025. F3 · derivative.expiration_date: The restricted stock units were received in lieu of cash payments to the reporting person for certain retainer and Board of Director service-related fees under a deferred compensation program applicable to participating non-employee directors. Release of vested restricted stock units will occur according to the elected deferral schedule. F4 · derivative.expiration_date: 528 shares vested on May 22, 2024, 528 shares will vest on August 22, 2024, 528 shares will vest on November 22, 2024 and 528 shares will vest on February 22, 2025. Read SEC document |
| May 22, 2024 Filed May 23, 2024 22:31 UTC | QuidelOrtho Corp QDEL · Entity 4986 | GrantRestricted Stock Units (Equity Grant) · Derivative | 4,929 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-064151 · ownership.xml · derivative · entry 1 WIDDER KENNETH J · CIK 0001065168 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,929 Underlying: Common Stock · 4,929 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of QuidelOrtho Corporation common stock. F2 · derivative.exercise_date: The restricted stock units vest on May 22, 2025. F2 · derivative.expiration_date: The restricted stock units vest on May 22, 2025. Read SEC document |
| May 22, 2024 Filed May 24, 2024 20:55 UTC | Evoke Pharma Inc EVOK · Entity 71094 | GrantStock Option (Right to Buy) · Derivative | 14,250 | $0.00 Strike: $0.45 | $0.00 |
DisclosureSEC source: 0000950170-24-064691 · ownership.xml · derivative · entry 1 WIDDER KENNETH J · CIK 0001065168 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,250 Underlying: Common Stock · 14,250 shares Expires 2034-05-21 F1 · derivative.exercise_date: The total number of shares of common stock subject to the option vests on the one-year anniversary of the date of grant, subject to the Reporting Person's continued service to the Issuer through such vesting date. Read SEC document |
| May 17, 2024 Filed May 22, 2024 01:10 UTC | Personalis, Inc. PSNL · Entity 4572 | GrantStock Option (right to buy) · Derivative | 50,000 | $0.00 Strike: $1.40 | $0.00 |
DisclosureSEC source: 0001415889-24-014038 · form4-05222024_010512.xml · derivative · entry 1 WIDDER KENNETH J · CIK 0001065168 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2034-05-17 F1 · derivative.exercise_date: 100% of the shares subject to the option shall vest on the earlier of the one-year anniversary of the grant date or the day prior to the Company's next annual meeting of stockholders occurring after the grant date, subject to the reporting person's Continuous Service (as defined in the Company's 2019 Equity Incentive Plan) through the vesting date. In the event of a Change in Control (as defined in the Company's 2019 Equity Incentive Plan), the shares underlying the option shall vest and become immediately exercisable prior to the effectiveness of such Change in Control. Read SEC document |
| May 12, 2024 Filed May 14, 2024 21:58 UTC | QuidelOrtho Corp QDEL · Entity 4986 | Exercise / conversionRestricted Stock Units (Premium) · Derivative | 98 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-059826 · ownership.xml · derivative · entry 4 WIDDER KENNETH J · CIK 0001065168 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 98 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of QuidelOrtho Corporation common stock. F3 · derivative.exercise_date: Release of restricted stock units was deferred pursuant to QuidelOrtho's deferred compensation program applicable to participating non-employee directors and occurred according to the elected deferred schedule. F3 · derivative.expiration_date: Release of restricted stock units was deferred pursuant to QuidelOrtho's deferred compensation program applicable to participating non-employee directors and occurred according to the elected deferred schedule. Read SEC document |
| May 12, 2024 Filed May 14, 2024 21:58 UTC | QuidelOrtho Corp QDEL · Entity 4986 | Exercise / conversionRestricted Stock Units (Converted) · Derivative | 328 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-059826 · ownership.xml · derivative · entry 3 WIDDER KENNETH J · CIK 0001065168 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 328 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of QuidelOrtho Corporation common stock. F3 · derivative.exercise_date: Release of restricted stock units was deferred pursuant to QuidelOrtho's deferred compensation program applicable to participating non-employee directors and occurred according to the elected deferred schedule. F3 · derivative.expiration_date: Release of restricted stock units was deferred pursuant to QuidelOrtho's deferred compensation program applicable to participating non-employee directors and occurred according to the elected deferred schedule. Read SEC document |
| May 12, 2024 Filed May 14, 2024 21:58 UTC | QuidelOrtho Corp QDEL · Entity 4986 | GrantCommon Stock | 98 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-059826 · ownership.xml · nonDerivative · entry 2 WIDDER KENNETH J · CIK 0001065168 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,723 F1 · shares: Reflects release of restricted stock units that were previously reported on a Form 4. Read SEC document |
| May 12, 2024 Filed May 14, 2024 21:58 UTC | QuidelOrtho Corp QDEL · Entity 4986 | GrantCommon Stock | 328 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-059826 · ownership.xml · nonDerivative · entry 1 WIDDER KENNETH J · CIK 0001065168 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,625 F1 · shares: Reflects release of restricted stock units that were previously reported on a Form 4. Read SEC document |
| June 13, 2023 Filed Jun 14, 2023 22:20 UTC | Personalis, Inc. PSNL · Entity 4572 | GrantStock Option (Right to Buy) · Derivative | 80,000 | $0.00 Strike: $2.31 | $0.00 |
DisclosureSEC source: 0001209191-23-037147 · doc4.xml · derivative · entry 1 WIDDER KENNETH J · CIK 0001065168 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 80,000 Underlying: Common Stock · 80,000 shares Expires 2033-06-12 F1 · derivative.exercise_date: The shares subject to the option vest in 3 annual installments with the first installment vesting on June 13, 2024. Read SEC document |
| June 06, 2023 Filed Jun 8, 2023 20:31 UTC | QuidelOrtho Corp QDEL · Entity 4986 | Exercise / conversionRestricted Stock Units (Equity Grant) · Derivative | 2,248 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-035427 · doc4.xml · derivative · entry 2 WIDDER KENNETH J · CIK 0001065168 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,248 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of QuidelOrtho Corporation common stock. F3 · derivative.exercise_date: The restricted stock units vested on June 6, 2023. F3 · derivative.expiration_date: The restricted stock units vested on June 6, 2023. Read SEC document |
| June 06, 2023 Filed Jun 8, 2023 20:31 UTC | QuidelOrtho Corp QDEL · Entity 4986 | GrantCommon Stock | 2,248 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-035427 · doc4.xml · nonDerivative · entry 1 WIDDER KENNETH J · CIK 0001065168 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,297 F1 · shares: Reflects release of restricted stock units that were previously reported on a Form 4. Read SEC document |
| May 24, 2023 Filed May 26, 2023 00:22 UTC | QuidelOrtho Corp QDEL · Entity 4986 | GrantRestricted Stock Units (Premium) · Derivative | 293 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-032336 · doc4.xml · derivative · entry 3 WIDDER KENNETH J · CIK 0001065168 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 293 Underlying: Common Stock · 293 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of QuidelOrtho Corporation common stock. F2 · derivative.exercise_date: The restricted stock units vest on May 24, 2024. F3 · derivative.exercise_date: The restricted stock units were received in lieu of cash payments to the reporting person for certain retainer and Board of Director service-related fees under a deferred compensation program applicable to participating non-employee directors. Release of vested restricted stock units will occur according to the elected deferral schedule. F2 · derivative.expiration_date: The restricted stock units vest on May 24, 2024. F3 · derivative.expiration_date: The restricted stock units were received in lieu of cash payments to the reporting person for certain retainer and Board of Director service-related fees under a deferred compensation program applicable to participating non-employee directors. Release of vested restricted stock units will occur according to the elected deferral schedule. Read SEC document |
| May 24, 2023 Filed May 26, 2023 00:22 UTC | QuidelOrtho Corp QDEL · Entity 4986 | GrantRestricted Stock Units (Converted) · Derivative | 978 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-032336 · doc4.xml · derivative · entry 2 WIDDER KENNETH J · CIK 0001065168 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 978 Underlying: Common Stock · 978 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of QuidelOrtho Corporation common stock. F3 · derivative.exercise_date: The restricted stock units were received in lieu of cash payments to the reporting person for certain retainer and Board of Director service-related fees under a deferred compensation program applicable to participating non-employee directors. Release of vested restricted stock units will occur according to the elected deferral schedule. F4 · derivative.exercise_date: The restricted stock units vest on the date of the grant, May 24, 2023. F3 · derivative.expiration_date: The restricted stock units were received in lieu of cash payments to the reporting person for certain retainer and Board of Director service-related fees under a deferred compensation program applicable to participating non-employee directors. Release of vested restricted stock units will occur according to the elected deferral schedule. F4 · derivative.expiration_date: The restricted stock units vest on the date of the grant, May 24, 2023. Read SEC document |
| May 24, 2023 Filed May 26, 2023 00:22 UTC | QuidelOrtho Corp QDEL · Entity 4986 | GrantRestricted Stock Units (Equity Grant) · Derivative | 2,416 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-032336 · doc4.xml · derivative · entry 1 WIDDER KENNETH J · CIK 0001065168 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,416 Underlying: Common Stock · 2,416 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of QuidelOrtho Corporation common stock. F2 · derivative.exercise_date: The restricted stock units vest on May 24, 2024. F2 · derivative.expiration_date: The restricted stock units vest on May 24, 2024. Read SEC document |
| May 14, 2023 Filed May 16, 2023 22:22 UTC | QuidelOrtho Corp QDEL · Entity 4986 | Exercise / conversionRestricted Stock Units (Premium) · Derivative | 315 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-029934 · doc4.xml · derivative · entry 4 WIDDER KENNETH J · CIK 0001065168 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 315 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of QuidelOrtho Corporation common stock. F3 · derivative.exercise_date: Release of restricted stock units was deferred pursuant to QuidelOrtho's deferred compensation program applicable to participating non-employee directors and occurred according to the elected deferred schedule. F3 · derivative.expiration_date: Release of restricted stock units was deferred pursuant to QuidelOrtho's deferred compensation program applicable to participating non-employee directors and occurred according to the elected deferred schedule. Read SEC document |
| May 14, 2023 Filed May 16, 2023 22:22 UTC | QuidelOrtho Corp QDEL · Entity 4986 | Exercise / conversionRestricted Stock Units (Converted) · Derivative | 1,050 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-029934 · doc4.xml · derivative · entry 3 WIDDER KENNETH J · CIK 0001065168 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,050 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of QuidelOrtho Corporation common stock. F3 · derivative.exercise_date: Release of restricted stock units was deferred pursuant to QuidelOrtho's deferred compensation program applicable to participating non-employee directors and occurred according to the elected deferred schedule. F3 · derivative.expiration_date: Release of restricted stock units was deferred pursuant to QuidelOrtho's deferred compensation program applicable to participating non-employee directors and occurred according to the elected deferred schedule. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.